Cambridge, MA | March 2023
Clear Scientific, Inc., a leading biopharmaceutical company developing novel therapies for treating life-threatening and debilitating conditions caused by an excess of harmful substances in the body, today announced that Dr. Marc Rubin and Dr. Roneet Lev have joined its Advisory Board.
Clear Scientific has a platform of small-molecule sequestrants that bind, inactivate, and clear harmful substances from the body with high specificity, which the company has applied to treatment areas including overdose caused by methamphetamine, fentanyl, cocaine and their co-use, as well as metabolic and neurodegenerative condition-induced CNS dysfunction.
Roneet Lev, MD FACEP is a nationally-acclaimed emergency and addiction medicine physician, with extensive experience in the treatment of patients with substance abuse disorders. She currently practices as a physician at Scripps Mercy Hospital, a leading center for treating emergency cases of substance abuse disorder in San Diego, CA. She previously served as the Chief Medical Officer for the White House Office of National Drug Control Policy. She established and previously chaired the San Diego Prescription Drug Abuse Medical Task Force, the first of its kind in California that integrated physicians of various specialties along with hospitals, law enforcement, hospital administration, treatment programs and public health for the purpose of decreasing deaths and mortality from prescription drugs. Dr. Lev has served as President of the California Chapter of the American College of Emergency Physicians, and is the Founder and President of IEPC, Independent Emergency Physicians Consortium, an organization providing collaboration to independent emergency departments in California. Dr. Lev also hosts “High Truths on Drugs and Addiction,” a podcast where national experts such as Dr. Nora Volkow, Director of the National Institute of Drug Abuse (NIDA) of the NIH, share facts and best practices.
Marc Rubin, MD, is a member of the Board of Directors of Titan Pharmaceuticals, (previously holding the positions of Chief Executive Officer and Executive Chairman of the Board of Directors of Titan Pharmaceuticals) and is a member of the Board of Directors of Curis Inc., and Galectin Therapeutics. Dr. Rubin has over 30 years of experience in the biopharmaceutical industry, with a focus on drug development and commercialization. Dr. Rubin previously served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the Merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Board of Executive Directors of Schering AG, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions with responsibility for global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America.
"We are delighted to welcome Dr. Rubin and Dr. Lev to our Advisory Board," said Shekar Shetty, CEO of Clear Scientific, Inc. "Their expertise and experience will be invaluable as we continue to develop innovative sequestrant-based therapeutics to address the most pressing public health challenges of our time."
"I am thrilled to be joining the Advisory Board of Clear Scientific, Inc.," said Dr. Rubin. "The company has a very novel approach to treating disease by rapidly removing drugs such as fentanyl, methamphetamine, and cocaine, from the body. The team at Clear Scientific has done a fantastic job in advancing potentially groundbreaking therapies toward the clinic. I look forward to working with the team to help bring these therapies to patients."
I am excited to be part of the Clear Scientific, Inc. Advisory Board," said Dr. Lev. "We need the medications developed by Clear Scientific - yesterday. There is nothing like them on the market and they will revolutionize the treatment for acute drug poisoning.”
For more information, please visit www.clearsci.com